The challenge of new drug discovery for tuberculosis

被引：0
|
作者：
Anil Koul
Eric Arnoult
Nacer Lounis
Jerome Guillemont
Koen Andries
机构：
[1] Janssen Research and Development,Department of Antimicrobial Research
[2] Johnson & Johnson,Department of Antimicrobial Research
[3] Turnhoutseweg 30,undefined
[4] B-2340 Beerse,undefined
[5] Belgium,undefined
[6] Janssen Research and Development,undefined
[7] Johnson & Johnson,undefined
[8] Val de Reuil 27106,undefined
[9] Cedex,undefined
[10] France,undefined
来源：
Nature | 2011年 / 469卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Although vaccination has been successful in some countries, tuberculosis (TB) is more prevalent in the world today than ever before, with nearly 10 million new cases expected yearly. Anil Koul and colleagues report on the various new TB drugs and treatment regimens under development. The prospects for some of them are good, they conclude, but the TB pathogen Mycobacterium tuberculosis deploys a range of mechanisms to evade host-control measures, so it will be important to keep the drugs pipeline well supplied. In addition, successful control of TB will depend on economic and societal measures to bolster health-care infrastructure in developing countries where TB is particularly prevalent.
引用
收藏
页码：483 / 490
页数：7
相关论文
共 50 条
  • [1] The challenge of new drug discovery for tuberculosis
    Koul, Anil
    Arnoult, Eric
    Lounis, Nacer
    Guillemont, Jerome
    Andries, Koen
    [J]. NATURE, 2011, 469 (7331) : 483 - 490
  • [2] MEETING THE CHALLENGE OF CARDIOVASCULAR NEW DRUG DISCOVERY
    SMITH, RD
    [J]. DRUG DEVELOPMENT RESEARCH, 1984, 4 (03) : 237 - 240
  • [3] Tuberculosis Drug Discovery: Challenges and New Horizons
    Fernandes, Guilherme F. S.
    Thompson, Andrew M.
    Castagnolo, Daniele
    Denny, William A.
    Dos Santos, Jean L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (11) : 7489 - 7531
  • [4] Discovery of new polymorphs of the tuberculosis drug isoniazid
    Zhang, Keke
    Fellah, Noalle
    Shtukenberg, Alexander G.
    Fu, Xiaoyan
    Hu, Chunhua
    Ward, Michael D.
    [J]. CRYSTENGCOMM, 2020, 22 (16) : 2705 - 2708
  • [5] A new concept for anti-tuberculosis drug discovery
    Grzelak, E. M.
    Choules, M.
    Hwang, C. H.
    Nam, J. W.
    Mulugeta, S. G.
    McAlpine, J. B.
    Cai, G.
    Gao, W.
    Lankin, D. C.
    Napolitano, J. G.
    Suh, J. W.
    Yang, S. H.
    Cheng, J.
    Kim, J.
    Cho, S. H.
    Pauli, G. F.
    Franzblau, S. G.
    Jaki, B. U.
    [J]. PLANTA MEDICA, 2014, 80 (10) : 759 - 759
  • [6] New approaches to filling the gap in tuberculosis drug discovery
    Casenghi, Martina
    Cole, Stewart T.
    Nathan, Carl F.
    [J]. PLOS MEDICINE, 2007, 4 (11) : 1722 - 1725
  • [7] Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
    Machado, Diana
    Girardini, Miriam
    Viveiros, Miguel
    Pieroni, Marco
    [J]. FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [8] Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
    Campanico, Andre
    Moreira, Rui
    Lopes, Francisca
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 525 - 545
  • [9] The Untapped Opportunity and Challenge of Immunometabolism: A New Paradigm for Drug Discovery
    Mazumdar, Claire
    Driggers, Edward M.
    Turka, Laurence A.
    [J]. CELL METABOLISM, 2020, 31 (01) : 26 - 34
  • [10] Drug Resistant Tuberculosis: A Worldwide Epidemic Poses a New Challenge
    Hundeiker, Max
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2010, 107 (24): : 435 - 435
12345